Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Part of paid clinical trials in San Francisco, California.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT01222689
Phase
PHASE2
Status
Completed

Conditions

  • Adenocarcinoma of the Pancreas
  • Recurrent Pancreatic Cancer
  • Stage III Pancreatic Cancer
  • Stage IV Pancreatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase II trial studies how well giving selumetinib and erlotinib hydrochloride together works in treating patients with locally advanced or metastatic pancreatic cancer that is refractory to chemotherapy. Selumetinib and erlotinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date
Nov 30, 2010
Status verified
Jul 2020
Primary completion
Apr 30, 2013
Completion
Sep 30, 2014

Study Design

Enrollment
46 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (erlotinib hydrochloride, selumetinib)
    Patients receive selumetinib PO QD and erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Overall Survival (OS) [ Time Frame: Up to 2 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
UCSF-Mount ZionSan FranciscoCalifornia94115-
Ohio State University Medical CenterColumbusOhio43210-

Find similar trials in San Francisco, CA

By research site
UCSF-Mount Zion· San Francisco, CAOhio State University Medical Center· Columbus, OH

Related Studies